U.S. Markets closed
  • S&P Futures

    4,389.25
    -13.75 (-0.31%)
     
  • Dow Futures

    34,795.00
    -156.00 (-0.45%)
     
  • Nasdaq Futures

    15,089.50
    -8.50 (-0.06%)
     
  • Russell 2000 Futures

    2,188.90
    -16.20 (-0.73%)
     
  • Crude Oil

    71.81
    -0.26 (-0.36%)
     
  • Gold

    1,806.30
    +4.50 (+0.25%)
     
  • Silver

    25.34
    +0.11 (+0.42%)
     
  • EUR/USD

    1.1779
    +0.0008 (+0.0707%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • Vix

    17.20
    -0.49 (-2.77%)
     
  • GBP/USD

    1.3751
    -0.0003 (-0.0192%)
     
  • USD/JPY

    110.3560
    -0.1540 (-0.1394%)
     
  • BTC-USD

    38,401.61
    +4,298.74 (+12.61%)
     
  • CMC Crypto 200

    915.38
    +121.64 (+15.33%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,918.50
    +370.50 (+1.34%)
     

Why You Shouldn't Bet Against Pacira BioSciences (PCRX) Stock

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

One stock that might be an intriguing choice for investors right now is Pacira BioSciences, Inc. PCRX. This is because this security in the Medical - Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Drugs space as it currently has a Zacks Industry Rank of 60 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Pacira BioSciences is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Pacira Pharmaceuticals, Inc. Price and Consensus

Pacira Pharmaceuticals, Inc. Price and Consensus
Pacira Pharmaceuticals, Inc. Price and Consensus

Pacira Pharmaceuticals, Inc. price-consensus-chart | Pacira Pharmaceuticals, Inc. Quote

In fact, over the past month, current quarter estimates have risen from 41 cents per share to 46 cents per share, while current year estimates have risen from $2.19 per share to $2.54 per share. This has helped PCRX to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position .You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Pacira BioSciences. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pacira Pharmaceuticals, Inc. (PCRX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.